×
TScan Therapeutics EBITDA 2020-2025 | TCRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TScan Therapeutics ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
TScan Therapeutics EBITDA 2020-2025 | TCRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TScan Therapeutics ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.9B
Amgen (AMGN)
$155B
Gilead Sciences (GILD)
$141.4B
Vertex Pharmaceuticals (VRTX)
$99.8B
Bristol Myers Squibb (BMY)
$96.9B
GSK (GSK)
$81.3B
CSL (CSLLY)
$67.8B
Regeneron Pharmaceuticals (REGN)
$62.2B
Alnylam Pharmaceuticals (ALNY)
$59.5B
Argenex SE (ARGX)
$43.3B
Insmed (INSM)
$28.4B
BioNTech SE (BNTX)
$24.8B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20B
Incyte (INCY)
$16.6B
Genmab (GNMSF)
$16B
Genmab (GMAB)
$15.9B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.8B
BioMarin Pharmaceutical (BMRN)
$11.3B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.7B
Exelixis (EXEL)
$10.4B
Moderna (MRNA)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Exact Sciences (EXAS)
$8.8B
Bio-Techne Corp (TECH)
$8.8B
Halozyme Therapeutics (HALO)
$8.6B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.2B